Finance Report
`2016
`
`Page 1
`
`Pfizer v. Genentech
`IPR2017-01488
`Genentech Exhibit 2029
`
`

`

`1)Total MabThera/Rituxan sales of CHF 7,300 million (2015: CHF 7,045 million) split between oncology and immunology franchises.
`
` 37,331
`
`39,103
`
`Total sales
`
`3,456
`1,508
`328
`512
`1,108
`
`657
`367
`290
`
` 1,520
` 1,520
`
`1,406
`1,406
`
` 23,661
`763
`128
` 513
` 769
` 1,181
` 1,445
` 5,640
` 6,538
`6,684
`
`1,773
`116
`259
` 298
`306
`794
`
`6,970
`104
`685
`741
`768
`1,477
`1,498
`1,697
`
`24,841
`1,050
`196
`506
`831
`1,024
`1,846
`5,823
`6,782
`6,783
`
`(CHF m)
`2015
`
`(CHF m)
`2016
`
`Total other therapeutic areas
`Others
`NeoRecormon/Epogin
`Mircera
`Activase/TNKase
`Other therapeutic areas
`
`Total Neuroscience
`Others
`Madopar
`Neuroscience
`
`Total Ophthalmology
`Lucentis
`Ophthalmology
`
`Total Infectious diseases
`Others
`Pegasys
`Rocephin
`Valcyte/Cymevene
`Tamiflu
`Infectious diseases
`
`Total Immunology
`Others
`Pulmozyme
`CellCept
`Esbriet
`MabThera/Rituxan 1)
`Xolair
`Actemra/RoActemra
`Immunology
`
`Total Oncology
`Others
`Gazyva/Gazyvaro
`Xeloda
`Kadcyla
`Tarceva
`Perjeta
`MabThera/Rituxan 1)
`Herceptin
`Avastin
`Oncology
`
`Pharmaceuticals Division – Sales
`
`Product sales
`
`Discount Program.
`Rituxan and Herceptin, were negatively impacted by an increase in reserves for mandatory discounts to hospitals under the 340B Drug
`were stable with the lower US sales offset by growth in the International region, particularly in China. Sales in the US, notably of MabThera/
`from Xolair and Esbriet sales in the US. MabThera/Rituxan sales continued to grow, especially in the US, China and Germany. Avastin sales
`uptake of Kadcyla. Sales increases in immunology mainly came from increasing use of Actemra/RoActemra in Europe and the US, and
`The growth of 8% in the HER2 franchise resulted from increased demand for Perjeta and Herceptin in combination therapy and continued
`
`10 | Roche Finance Report 2016
`
`Alecensa, Tecentriq and Cotellic added CHF 0.4 billion of sales.
`under competitive pressure and sales of Valcyte/Cymevene decreased due to generic competition. The recently launched products
`contributed CHF 1.4 billion at CER to sales growth in 2016. Sales of Pegasys, Tarceva and Lucentis declined by a total of CHF 0.6 billion
`growth was primarily driven by Perjeta, Herceptin, Actemra/RoActemra, MabThera/Rituxan, Esbriet and Xolair. These products together
`Pharmaceuticals Division sales increased by 3% at CER to CHF 39.1 billion led by growth in oncology and immunology products. Sales
`
`100
`9
`
`4
`
`2
`
`5
`17
`63
`(2015)
`% of sales
`
`100
`7
`
`4
`
`2
`
`5
`18
`64
`(2016)
`% of sales
`
`+3
`+3
`+2
`–10
`–14
`+10
`+4
`(CER)
`% change
`
` 37,331
` 3,223
`648
` 1,520
` 2,051
`6,228
`23,661
`(CHF m)
`2015
`
`39,103
`3,456
`657
`1,406
`1,773
`6,970
`24,841
`(CHF m)
`2016
`
`–3.5
`–6
`
`–2
`–2
`
`0
`
`+0.4
`+4
`–23
`+4
`+3
`+1
`–10
`+3
`
`–0.7
`+1
`–52
`+20
`+2
`–1
`–10
`+3
`
`–3.4
`–4
`
`0
`
`0
`
`+3
`
`+0.2
`+5
`–22
`+6
`+5
`+3
`–8
`+5
`
`–0.8
`+2
`–51
`+21
`+4
`+1
`–8
`+5
`
` 38.8
`14,482
`
`30,616
`26,179
`4,437
`
`43.0
`16,055
`(1,295)
`(8,134)
`(6,066)
`(7,900)
`2,119
`37,331
`
`34.8
`13,003
`(1,677)
`(8,367)
`(6,154)
`(10,249)
`
`2,119
`37,331
`
`(CER)
`% change
`
`(CHF)
`% change
`
`(CHF m)
`2015
`
`35.4
`13,859
`
`30,756
`26,174
`4,582
`
`43.2
`16,909
`(1,013)
`(8,588)
`(6,362)
`(8,175)
`1,944
`39,103
`
`34.0
`13,285
`(822)
`(10,156)
`(6,391)
`(10,393)
`1,944
`39,103
`
`(CHF m)
`2016
`
`Total sales
`Other therapeutic areas
`Neuroscience
`Ophthalmology
`Infectious diseases
`Immunology
`Oncology
`Therapeutic area
`
`Pharmaceuticals Division – Sales by therapeutic area
`
`Sales overview
`
`1)See pages 137–140 for the definition of Core results and Core EPS.
`
`–margin, % of sales
`Operating free cash flow
`Free cash flow
`
`Net operating assets
`Long-term net operating assets
`Net working capital
`Financial position
`
`Page 2
`
`–margin, % of sales
`Core operating profit
`General and administration
`Research and development
`Marketing and distribution
`Cost of sales
`Royalties and other operating income
`Sales
`Core results 1)
`
`–margin, % of sales
`Operating profit
`General and administration
`Research and development
`Marketing and distribution
`Cost of sales
`Royalties and other operating income
`Sales
`IFRS results
`
`Pharmaceuticals Division operating results
`
`Pharmaceuticals Division operating results
`
`Roche Group | Financial Review
`
`Roche Finance Report 2016 | 11
`
`100
`
`100
`
`3
`
`1
`
`1
`
`4
`
`9
`
`2
`1
`
`1
`
`4
` 4
`
`1
`
`0
`
`5
`
`1
`
`2
`
`1
`
`17
`
`4
`
`3
`
`4
`
`2
`
`2
`
`2
`
`0
`
`63
`
`0
`
`2
`
`1
`2
`3
`4
`15
`18
`18
`
`2
`
`1
`
`1
`
`3
`
`7
`
`2
`
`1
`
`1
`
`2
`
`1
`
`1
`
`1
`
`0
`
`5
`
`4
`
`4
`
`18
`
`4
`
`4
`
`4
`
`2
`
`2
`
`2
`
`0
`
`64
`
`1
`
`2
`
`1
`2
`2
`5
`15
`18
`18
`
`+3
`
`+3
`–2
`–9
`+2
`+16
`
`+2
`–1
`+6
`
`–10
`–10
`
`–14
`–27
`–52
`+7
`–17
`+10
`
`+10
`–18
`+4
`–6
`+34
`+5
`+15
`+16
`
`+4
`+33
`+52
`–3
`+7
`–15
`+26
`+2
`+4
`
`0
`
`(2015)
`% of sales
`
`(2016)
`% of sales
`
`(CER)
`% change
`
`3,223
`1,447
`366
`475
` 935
`
` 648
` 373
`275
`
`2,051
`160
`538
`279
`369
`705
`
`6,228
`114
`652
`785
`563
`1,405
`1,277
`1,432
`
`Financial Review | Roche Group
`
`